Robert H. Beekman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robert H. Beekman has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey B. Anderson
Cincinnati Children’s Hospital Medical Center
2 shared publications Brian W. Duncan
Division of Cardiac Surgery, Cleveland Clinic Foundation, Cleveland, Ohio
1 shared publication- Carole M. Lannon
James M. Anderson Center for Health Systems Excellence, Cincinnati Children’s Hospital and Senior Quality Advisor, American Board of Pediatrics (C.M.L.).
1 shared publication Donald J. Hagler
Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota
1 shared publication- Gerard R. Martin
Children’s National Hospital, Washington, DC 20010, USA
1 shared publication Jamie S. Sutherell
Division of Cardiology, The Heart Institute at Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
1 shared publication
Latest Publications
- 17 October 2014
- Published by Springer Nature
- p. 51-67
Quality Improvement in Pediatric Cardiology: The National Pediatric Cardiology Quality Improvement Collaborative
- 17 October 2014
- Published by Springer Nature
- p. 51-67
Quality Improvement in Pediatric Cardiology: The National Pediatric Cardiology Quality Improvement Collaborative
- 17 October 2014
- Published by Springer Nature
- p. 153-163
Addressing Nutrition and Growth in Children with Congenital Heart Disease
- 17 October 2014
- Published by Springer Nature
- p. 153-163
Addressing Nutrition and Growth in Children with Congenital Heart Disease
- 1 January 2010
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 5 (1) , 2-7
Pediatric Interventional Cardiology in the United States is Dependent on the Off-label Use of Medical Devices
A substantial unmet medical device need exists in pediatric care. As a result, the off-label use of approved devices is routine in pediatric interventional cardiology, but the extent and nature of this practice has not been previously described. The purpose of this study, therefore, is to evaluate the prevalence and nature of off-label cardiac device use in an active pediatric interventional program in the United States. This study is a retrospective review of all interventional cardiac procedures performed at our institution from July 1, 2005 to June 30, 2008. Diagnostic (noninterventional) catheterizations, myocardial biopsies, invasive electrophysiology studies, and studies involving investigational devices were excluded. Interventions performed were compared with the manufacturer's labeled indications for each device. During this 3-year period, 473 patients (median age 4.1 years) underwent 595 transcatheter interventions. An approved device was utilized for an off-label application in 63% of patients, and in 50% of all interventions performed. The most frequent off-label procedures were stent implantations (99% off-label), balloon dilations (78% off-label), and coil embolizations (29% off-label). In contrast, the off-label use of septal and ductal occluders was relatively uncommon. In our routine (noninvestigational) practice of pediatric interventional cardiology, 63% of patients underwent procedures utilizing medical devices for off-label indications. These data underscore the need to enhance cardiac device review and approval processes in the United States to include pediatric applications.
- 1 January 2010
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 5 (1) , 2-7
Pediatric Interventional Cardiology in the United States is Dependent on the Off-label Use of Medical Devices
A substantial unmet medical device need exists in pediatric care. As a result, the off-label use of approved devices is routine in pediatric interventional cardiology, but the extent and nature of this practice has not been previously described. The purpose of this study, therefore, is to evaluate the prevalence and nature of off-label cardiac device use in an active pediatric interventional program in the United States. This study is a retrospective review of all interventional cardiac procedures performed at our institution from July 1, 2005 to June 30, 2008. Diagnostic (noninterventional) catheterizations, myocardial biopsies, invasive electrophysiology studies, and studies involving investigational devices were excluded. Interventions performed were compared with the manufacturer's labeled indications for each device. During this 3-year period, 473 patients (median age 4.1 years) underwent 595 transcatheter interventions. An approved device was utilized for an off-label application in 63% of patients, and in 50% of all interventions performed. The most frequent off-label procedures were stent implantations (99% off-label), balloon dilations (78% off-label), and coil embolizations (29% off-label). In contrast, the off-label use of septal and ductal occluders was relatively uncommon. In our routine (noninvestigational) practice of pediatric interventional cardiology, 63% of patients underwent procedures utilizing medical devices for off-label indications. These data underscore the need to enhance cardiac device review and approval processes in the United States to include pediatric applications.
- 1 July 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 124 (1) , e155-e162
Pathways to Approval of Pediatric Cardiac Devices in the United States: Challenges and Solutions
Patients treated by pediatric interventional cardiologists and cardiac surgeons often have unmet medical device needs that pose a challenge to the current regulatory evaluation and approval process in the United States. In this report we review current US Food and Drug Administration regulatory processes, review some unique aspects of pediatric cardiology and cardiac surgery that pose challenges to these processes, and discuss possible alternate pathways to cardiac device evaluation and approval for children. Children deserve to benefit from new and refined cardiac devices and technology designed explicitly for their conditions.
- 1 July 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 124 (1) , e155-e162
Pathways to Approval of Pediatric Cardiac Devices in the United States: Challenges and Solutions
Patients treated by pediatric interventional cardiologists and cardiac surgeons often have unmet medical device needs that pose a challenge to the current regulatory evaluation and approval process in the United States. In this report we review current US Food and Drug Administration regulatory processes, review some unique aspects of pediatric cardiology and cardiac surgery that pose challenges to these processes, and discuss possible alternate pathways to cardiac device evaluation and approval for children. Children deserve to benefit from new and refined cardiac devices and technology designed explicitly for their conditions.
- 1 October 2005
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 18 (5) , 397-399
Myocardial Ischemia: Atypical Presentation of an Atrial Septal Defect in Childhood
We describe a 17-year-old male with a secundum atrial septal defect (ASD), who presented with acute myocardial ischemia. The presumptive diagnosis of a paradoxical coronary embolism was based on the demonstration of a large ASD in conjunction with normal coronary arteries, a negative endomyocardial biopsy, and a negative drug screen. After percutaneous closure with an Amplatzer device, there has been no recurrence for 2 years.
- 1 October 2005
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 18 (5) , 397-399
Myocardial Ischemia: Atypical Presentation of an Atrial Septal Defect in Childhood
We describe a 17-year-old male with a secundum atrial septal defect (ASD), who presented with acute myocardial ischemia. The presumptive diagnosis of a paradoxical coronary embolism was based on the demonstration of a large ASD in conjunction with normal coronary arteries, a negative endomyocardial biopsy, and a negative drug screen. After percutaneous closure with an Amplatzer device, there has been no recurrence for 2 years.